Cambridge, Massachusetts -- Pharmaceutical technology company Genetix Pharmaceuticals has raised $35 million in its second round of institutional venture capital investment.
Genetix is developing hemoglobin gene therapy technologies to treat life-threatening diseases.
Investors in the round included Third Rock Ventures, Genzyme Ventures, TVM Capital, Forbion Capital Partners and Easton Capital. The company said it would use the funding proceeds to advance its current clinical programs. |